Coronary heart disease is the number one killer of human, the common treatment is percutaneous coronary intervention, implanting metal stents, to expand the coronary lumen, restore myocardial blood flow.

   But there’s still a risk of restenosis of implanting metal stents, and drug coated stents can continue to release drugs to prevent restenosis. However, the emergence of bio absorbable stents provides more treatment for patients with coronary heart disease.

                                                                                         ◆  ◆  ◆  ◆  ◆

   On July 5, 2016, the FDA approved the first clinical application of fully absorbable stents in coronary artery disease, named Absorb GT1 BVS. Its outside coating can release everolimus to prevent restenosis, which will be slowly absorbed after about 3 years by human body.

   The material of BVS is man-made biodegradable polymer, similar to materials of absorption line and other implantable medical device. BVS can be slowly degraded in the human body, and finally remains 4 tube wall platinum markers to identify the location of the stent placement.

   As the accordance approved, ABSORB III research included 2008 patients, compared the impact on incidence of major adverse cardiac events of BVS and traditional drug coated stents, the one year follow-up results of the study showed the incidence of BVS group of major adverse cardiac events and thrombosis formation rate were slightly higher than that of the conventional stent group.

   Of course, there are contraindications of BVS. It includes everolimus or scaffold materials such as polymers and perkin allergy, and it is not suitable to do angioplasty, the contrast agent allergy etc.

                                                                                          ◆  ◆  ◆  ◆  ◆